Objective To explore the correlation between DNA load of drug-resistance mycoplasma pneumonia(MP) and 23sRNA mutation at 2063 locus in children, in order to provide evidence for the treatment of MP pneumonia. Methods A total of 158 children with MP pneumonia who were treated in Nantong First People's Hospital from December 2017 to December 2019 were enrolled in this study.The drug sensitivity tests were performed on all patients.According to the results of drug-resistance to antibiotics, patients were divided into resistance group(n=112) and non-resistance group(n=46).The MP load index(MPLI) and mutation rate of 23sRNA gene at 2063 locus were compared between resistance group and non-resistance group.The relationship between MPLI and clinical indexes was analyzed.The diagnostic value of MPLI for drug-resistance MP pneumonia was analyzed by ROC curves.The correlation between MPLI and mutation of 23sRNA gene at 2063 locus was analyzed. Results MPLI in resistance group was significantly lower than that in non-resistance group(t=4.373, P<0.001).AUC and cut-off value of MPLI for diagnosis of drug-resistance MP pneumonia were 0.698 and 5.16, respectively.The proportion of cases with defervescence time not shorter than 3 days, disappearance time of cough and expectoration not shorter than 5 days, disappearance time of chest shadow not shorter than 10 days and extrapulmonary complications in positive MPLI group was higher than that in negative MPLI group(χ2=17.584, 19.237, 44.724, 11.075, P<0.001).Multivariate Logistics regression analysis showed that defervescence time ≥3 days, disappearance time of cough and expectoration ≥5 days, disappearance time of chest shadow ≥10 days and extrapulmonary complications were influencing factors of MPLI expression in children with MP pneumonia(OR=1.420, 1.573, 1.670, 1.598, P<0.001).The mutation rate of 23sRNA gene at 2063 locus in resistance group was significantly higher than that in non-resistance group(χ2=52.484, P<0.001).The expression level of MPLI was negatively correlated with 23sRNA gene mutation at 2063 locus(r=-0.538, P<0.001). Conclusions The expression of MPLI is related to clinical indexes such as disappearance time of clinical symptoms in children with MP pneumonia, which is negatively related to the mutation rate of 23sRNA gene at 2063 locus.MPLI expression is of diagnostic value for drug-resistance MP pneumonia.
Key words
drug-resistance mycoplasma pneumonia /
children /
mycoplasma DNA load /
23sRNA gene mutation locus
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 刘调侠, 张晓瓒, 李延琴.儿童肺炎支原体感染及耐药检测与分析[J].西部医学, 2016, 28(11):1598-1602.
[2] Kumar S,Garg IB, Sethi GR, et al.Detection of immunoglobulin M and immunoglobulin G antibodies to Mycoplasma pneumoniae in children with community-acquired lower respiratory tract infections[J].Indian J Pathol Microbiol, 2018, 61(2):214-218.
[3] 张慧芬, 白海涛, 李基明,等.肺炎支原体肺炎患儿肺炎支原体耐药性与DNA载量和基因型的关系研究[J].中国当代儿科杂志, 2017, 19(11):1180-1184.
[4] 中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会.儿童社区获得性肺炎管理指南(2013修订)(下)[J].中华儿科杂志, 2013, 51(11):856-862.
[5] 马玉楠.体外生物诊断试剂申报技术要求[J].中国新药杂志, 2003, 12(6):482-485.
[6] 潘芬, 孟磊俊, 秦惠宏, 等.儿童肺炎支原体23SrRNA基因位点突变检测分析[J].国际检验医学杂志, 2017, 38(6):760-762.
[7] 王亚坤, 高文杰, 王伟,等.肺炎支原体突变敏感性分子开关检测对抗菌药物敏感性检测的作用研究[J].中国微生态学杂志, 2016, 28(8):926-929.
[8] 叶芸, 李苏亮, 姜萍, 等.肺炎支原体23SrRNA基因突变位点与耐药表型的分析[J].检验医学, 2013, 28(1):11-16.
[9] 陆燕, 吴鸣, 章爱莲, 等.儿童重症肺炎支原体肺炎临床特征及耐药基因突变研究[J].浙江医学教育, 2018, 17(1):52-54.
[10] 张涛, 王波, 王穗琼, 等.儿童肺炎支原体的耐药性与临床用药相关性研究[J].中华妇幼临床医学杂志(电子版), 2014, 10(1):28-33.
[11] Zhou Z, Li X, Chen X, et al.Comparison of P1 and 16SrRNA genes for detection of Mycoplasma pneumoniae by nested PCR in adults in Zhejiang, China[J].J Infec Dev Ctries, 2015, 9(3):244-253.
[12] 林艳, 马微, 李桂艳,等.医院儿童肺炎支原体的耐药性变迁分析[J].中国病原生物学杂志, 2017, 12(6):92-95.
[13] Copete AR, Aguilar YA, Rueda ZV, et al.Genotyping and macrolide resistance of, Mycoplasma pneumoniae, identified in children with community-acquired pneumonia in Medellín, Colombia[J].Int J Infec Dis, 2018, 66(2):113-120.
[14] 郭艳霞, 冯艳芳, 沈丹华, 等.DNA载量和基因型检测在MP肺炎患儿治疗中的临床作用研究[J].广西医科大学学报, 2019, 36(6):904-908.
[15] 朱美君, 宋磊, 周峰,等.23S rRNA基因突变与儿童肺炎支原体耐药机制相关性[J].海南医学, 2018, 29(3):75-78.
[16] 黎燕, 钟礼立, 张兵,等.23SrRNA V区A2063G基因突变的肺炎支原体肺炎患儿临床特征分析[J].临床儿科杂志, 2018, 36(8):7-12.
PDF(565 KB)
